Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced Unresectable or Metastatic Solid Tumors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06682793
What this trial is testing

Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Who this might be right for
Solid Tumor, AdultColorectal CancerNon-Small Cell Lung+14 more
A2 Biotherapeutics Inc. 240
Early research (Phase 1)Looking for participantsNCT05978492
What this trial is testing

TXN10128 in Subjects With Solid Tumors

Who this might be right for
Locally Advanced (Unresectable) or Metastatic Solid Tumors
Txinno Bioscience Inc. 96
Early research (Phase 1)Study completedNCT04641871
What this trial is testing

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

Who this might be right for
Metastatic CancerSolid Tumor
Symphogen A/S 78
Early research (Phase 1)Study completedNCT03311412
What this trial is testing

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Who this might be right for
Metastatic CancerSolid TumorLymphoma
Symphogen A/S 89
Not applicableActive Not RecruitingNCT05812027
What this trial is testing

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Who this might be right for
Head and Neck CancerCervical CancerNon Small Cell Lung Cancer+4 more
TScan Therapeutics, Inc. 1,150
Early research (Phase 1)Study completedNCT03523390
What this trial is testing

Phase I/Ib Multiple Ascending Dose Study in China

Who this might be right for
Metastatic Solid Tumors
Merck KGaA, Darmstadt, Germany 24
Testing effectiveness (Phase 2)Looking for participantsNCT07488676
What this trial is testing

ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Who this might be right for
Gastric or Gastro-esophageal Junction (GEJ) AdenocarcinomaPancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc. 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07762703
What this trial is testing

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

Who this might be right for
Triple-Negative Breast Cancer (TNBC)
BreakBio Corp 10
Early research (Phase 1)Ended earlyNCT06364696
What this trial is testing

Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

Who this might be right for
Solid Tumor
Astellas Pharma Inc 60
Testing effectiveness (Phase 2)Study completedNCT05991349
What this trial is testing

IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd. 36
Testing effectiveness (Phase 2)Looking for participantsNCT06051695
What this trial is testing

Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Who this might be right for
Solid Tumor, AdultColorectal CancerNSCLC+17 more
A2 Biotherapeutics Inc. 474
Testing effectiveness (Phase 2)Ended earlyNCT04547101
What this trial is testing

AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors

Who this might be right for
MSI-H/dMMR Solid Tumor
Akeso 6
Testing effectiveness (Phase 2)Looking for participantsNCT07819136
What this trial is testing

REC-7735 in Participants With Solid Tumors

Who this might be right for
Solid Tumors
Recursion Pharmaceuticals Inc. 90
Large-scale testing (Phase 3)Active Not RecruitingNCT06635824
What this trial is testing

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

Who this might be right for
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Genmab 191
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07752875
What this trial is testing

LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation

Who this might be right for
Ovarian CancerSmall Cell Lung CancerNon Small Cell Lung Cancer+7 more
LG Chem 250
Testing effectiveness (Phase 2)Study completedNCT00021047
What this trial is testing

Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor

Who this might be right for
Esophageal CancerExtrahepatic Bile Duct CancerGastric Cancer+3 more
National Institutes of Health Clinical Center (CC)
Testing effectiveness (Phase 2)Ended earlyNCT04032704
What this trial is testing

Ladiratuzumab Vedotin in Advanced Solid Tumors

Who this might be right for
Small Cell Lung CancerNon-small Cell Lung Cancer, SquamousNon-small Cell Lung Cancer, Non-squamous+6 more
Seagen Inc. 205
Testing effectiveness (Phase 2)Looking for participantsNCT07436728
What this trial is testing

TAK-505 in Adults With Solid Tumors

Who this might be right for
Malignant Solid Tumors
Takeda 151
Early research (Phase 1)Study completedNCT00010023
What this trial is testing

Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Cancer
NYU Langone Health
Testing effectiveness (Phase 2)Looking for participantsNCT05923008
What this trial is testing

A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd. 182
Next Page